Rein Therapeutics published a presentation for investors detailing its plans for the lung fibrosis drug candidate LTI-03 and caveolin scaffolding domains. The filing is a static investor materials update rather than a market-moving financial event.
Rein Therapeutics published a presentation for investors detailing its plans for the lung fibrosis drug candidate LTI-03 and caveolin scaffolding domains. The filing is a static investor materials update rather than a market-moving financial event.